Pemetrexed alone or in combination with cisplatin in previously treated patients with malignant pleural mesothelioma (MPM): Outcomes of an expanded access program (EAP).

被引：0
|
作者：
Orlando, M
Wozniak, A
Janne, P
Belani, CP
Keohan, ML
Ross, H
Polikoff, J
Mintzer, D
Bloss, L
Obasaju, C
机构：
[1] Lilly Res Labs, Indianapolis, IN USA
[2] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Columbia Presbyterian Med Ctr, New York, NY 10032 USA
[5] Oregon Hlth Sci Univ, Portland, OR 97201 USA
[6] Kaiser Hosp San Diego, San Diego, CA USA
[7] Penn Hosp, Philadelphia, PA 19107 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7195
引用
收藏
页码：664S / 664S
页数：1
相关论文
共 50 条
  • [31] Vinorelbine (V) in pemetrexed-pretreated patients (PTS) with malignant pleural mesothelioma (MPM)
    Lorenzi, E.
    Gianoncelli, L.
    Zucali, P.
    Ceresoli, G.
    De Vincenzo, F.
    Simonelli, M.
    Ripa, C.
    Giordano, L.
    Santoro, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] VINORELBINE (V) IN PEMETREXED-PRETREATED PATIENTS (PTS) WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM)
    De Vincenzo, F.
    Lorenzi, E.
    Zucali, P. A.
    Simonelli, M.
    Gianoncelli, L.
    Ceresoli, G. L.
    Ripa, C.
    Giordano, L.
    Santoro, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 161 - 161
  • [33] PEMETREXED/CARBOPLATIN(AC) OR PEMETREXED/CISPLATIN (AP) AS FIRST LINE TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA (MPM): TOLERABILITY AND RESPONSE RATE IN OPERABLE PATIENTS
    Pasello, Giulia
    Marulli, Giuseppe
    Nicotra, Samuele
    Rea, Federico
    Loreggian, Lucio
    Bonanno, Laura
    Favaretto, Adolfo
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1367 - S1368
  • [34] Value-for-money of pemetrexed plus cisplatin versus cisplatin alone in the treatment of malignant pleural mesothelioma
    Davey, P
    Cordony, A
    Rajan, N
    Arora, B
    Pavlakis, N
    VALUE IN HEALTH, 2005, 8 (03) : 238 - 239
  • [35] Survival of patients with advanced mesothelioma treated with cisplatin and pemetrexed combination
    Hirst, J.
    Dale, N.
    Hall, S.
    Smith, N.
    Mcdonald-Smith, C.
    Goshal, N.
    Gostage, A.
    Drury, G.
    Garcia-Alonso, A.
    LUNG CANCER, 2013, 79 : S32 - S32
  • [36] Pemetrexed in the treatment of malignant mesothelioma: Results from an expanded access program in Germany
    Reck, Martin
    Stahel, Rolf A.
    von Pawel, Joachim
    Karthaus, Meinolf
    Korfee, Soenke
    Serke, Monika
    Schuette, Wolfgang H. -W.
    Eschbach, Corinna
    Fink, Thomas H.
    Leschinger, Monika I.
    Manegold, Christian
    RESPIRATORY MEDICINE, 2010, 104 (01) : 142 - 148
  • [37] Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma (MPM)
    Krug, Lee M.
    Wozniak, Antoinette J.
    Kindler, Hedy Lee
    Feld, Ronald
    Koczywas, Marianna
    Morero, Jose Luis
    Rodriguez, Cristina P.
    Ross, Helen J.
    Bauman, Julie E.
    Orlov, Sergey V.
    Ruckdeschel, John C.
    Mita, Alain C.
    Fein, Luis
    Fernandez, Cristian
    Hall, Robert
    Kawabe, Takumi
    Sharma, Sunil
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Phase I study of sorafenib and cisplatin/pemetrexed regimen in untreated malignant pleural mesothelioma (MPM) patients: Italian SoMe Study
    Mutri, V.
    Pinto, C.
    Giaquinta, S.
    Di Tullio, P.
    Torri, V.
    Melotti, B.
    Sperandi, F.
    Di Fabio, F.
    Llimpe, F. L. Rojas
    Pini, S.
    Massari, F.
    Martoni, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] ONCOS-102 and pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma
    Ponce Aix, S.
    Viteri, S.
    Bosch-Borrera, J.
    Kuryk, L.
    Hakonen, T.
    Vetrhus, S.
    Jaderberg, M.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] Pemetrexed with or without a platinum compound in patients with malignant mesothelioma: A single institution "Expanded Access Program" experience
    Baas, P
    Burgers, S
    Lieverst, J
    Dalesio, O
    van Zandwijk, N
    LUNG CANCER, 2005, 49 : S219 - S219
12345